CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful diligently but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV happen to be closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the last several shares of mine. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire interview which I came away with a bad viewpoint of the business.

Irony of irony, the poor viewpoint of mine of the business enterprise has grown steadily, however, the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 million transfers ownership of this know-how as well as linked intellectual property from Progenics to CytoDyn, and approximately 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 million) along with the very first brand new drug program approval ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s helping nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with multiple indications and many therapies, it has this single treatments as well as a “broad pipeline of indications” as it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially advantageous therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit focused on leronlimab, multiple disease types, multiple publications in addition to multiple presentations.

Might it all be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this particular organization. Judging by way of the multiples of a huge number of diverse remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am much from alone in this particular question.

CytoDyn is a classic battleground, or maybe some may say cult inventory. Its adherents are fiercely protective of its prospects, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News